Table 2 Patients characteristics and treatment summary
From: Use of rituximab as an induction therapy in anti-glomerular basement-membrane disease
Patient | Initial clinical presentation | Creatinine at diagnosis | Iinitial dialysis | Crescents | Initial | ANCA | Number of plasma exchange sessions | Corticosteroids | Rituximab | Outcome | Complications | Follow up duration | Evolution |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
(μmol/L) | within 7 days after diagnosis | on biopsy | anti-GBM titer (IIF) | (months) | |||||||||
Patient 1 | general weakness, AKI | 706 | yes | 20% | 1/10 | negative | 9 | 120 mg ×3 + 1 mg/kg | 375 mg/m2 ×4 | ESRD | no | 39 | Transplantation |
Patient 2 | AKI with diarrhea, dyspnea and desaturation, alveolar hemorrhage | 800 | yes | 90% | 1/80 | positive, MPO | 23 | 1 mg/Kg | 375 mg/m2 ×4 | Pulmonary recovery, ESRD | no | 23 | Hemodialysis |
Patient 3 | hemoptysis, respiratory distress with mechanical ventilation, AKI in intensive care | 47 | no | NA | 1/5 | positive, non specific | 10 | 1 mg/kg | 375 mg/m2 ×4 | Pulmonary recovery | candida colonization | 4 | Creatinine 48 μmol/L |
Patient 4 | rapidly progressing glomerulonephritis, hematuria | 273 | yes | NA | 1/640 | negative | 21 | 500 mg × 4 + 1 mg/kg | 375 mg/m2 ×4 | ESRD | Esophageal candidiasis + temporary | 9 | Peritoneal dialysis |
thrombocytopenia | |||||||||||||
Patient 5 | hemoptysis,AKI | 605 | yes | 100% | 1/200 | negative | 20 | 500 mg × 3+ 1 mg/kg | 375 mg/m2 ×4 | Pulmonary recovery, ESRD | no | 14 | Transplantation |